Search Within

MSK Grad Students

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (397)
  2. Meeting Abstract (268)
  3. Editorial (8)
  4. Miscellaneous (8)
  5. Research Letter (8)
  6. Review (7)
  7. Conference Paper (2)
  8. Correspondence (1)
  9. Guidelines (1)
Groups
  1. Human Oncology and Pathogenesis Program (700)
  2. GSK Faculty (698)
  3. Department of Medicine (588)
  4. Sloan Kettering Institute Postdocs (478)
  5. Solid Tumor Oncology Division (372)
  6. Epidemiology and Biostatistics (358)

More Groups

People
  1. Nikolaus Schultz (148)
  2. Michael Berger (108)
  3. Vinod Balachandran (99)
  4. David Solit (96)
  5. William Jarnagin (93)
  6. Marcel Van Den Brink (91)

More People

Years
  1. 2025 (26)
  2. 2024 (86)
  3. 2023 (74)
  4. 2022 (100)
  5. 2021 (73)
  6. 2020 (104)

More Years

Publications
  1. Journal of Clinical Oncology (74)
  2. Cancer Research (71)
  3. Blood (66)
  4. Clinical Cancer Research (44)
  5. Annals of Surgical Oncology (39)
  6. Biology of Blood and Marrow Transplantation (30)

More Publications

Publishers
  1. American Association for Cancer Research (150)
  2. Nature Publishing Group (104)
  3. American Society of Clinical Oncology (85)
  4. American Society of Hematology (68)
  5. Cell Press (55)
  6. Elsevier Inc. (45)

More Publishers

Results (700)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients
    Journal Article

    Hallin, J.; Engstrom, L. D.; Hargis, L.; Calinisan, A.; Aranda, R.; Briere, D. M.; Sudhakar, N.; Bowcut, V.; Baer, B. R.; Ballard, J. A.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
    Journal Article

    Xue, J. Y.; Zhao, Y.; Aronowitz, J.; Mai, T. T.; Vides, A.; Qeriqi, B.; Kim, D.; Li, C.; de Stanchina, E.; Mazutis, L.; more...
    Nature (2020)

    Fulltext@MSK | Save
  • ID1 mediates escape from TGFβ tumor suppression in pancreatic cancer
    Journal Article

    Huang, Y. H.; Hu, J.; Chen, F.; Lecomte, N.; Basnet, H.; David, C. J.; Witkin, M. D.; Allen, P. J.; Leach, S. D.; Hollmann, T. J.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Graft versus host disease leads to elimination of tissue-resident innate lymphoid cells following experimental and clinical allogeneic transplantation
    Meeting Abstract

    Vinci, P.; Garcia-Martinez, E.; O'Connor, M. H.; Egorova, A.; Kuttiyara, J.; Arnhold, V.; Ponce, D. M.; Hanash, A. M.
    Blood (2019)

    Fulltext@MSK | Save
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Sparing of the lower gastrointestinal tract microbiota is associated with reduced acute graft-versus-host disease
    Meeting Abstract

    Ponce, D. M.; Burgos da Silva, M. D.; Gomes, A. L. C.; Moore, G.; Slingerland, J. B.; Pamer, E. G.; Taur, Y.; Peled, J. U.; van den Brink, M. R. M.
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Pre-transplant fecal microbial diversity independently predicts critical illness after hematopoietic cell transplantation
    Meeting Abstract

    Adhi, F. I.; Littmann, E. R.; Taur, Y.; Maloy, M. A.; Markey, K. A.; Fontana, E.; Amoretti, L. A.; Wright, R.; Sanchez-Escamilla, M.; Castillo Flores, N.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Graft-versus-host disease leads to systemic elimination of innate lymphoid cells and abolishes their development
    Meeting Abstract

    Vinci, P.; Garcia-Martinez, E.; O'Connor, M. H.; Egorova, A.; Mertelsmann, A. M.; Nicoletti, E.; Geary, C. D.; Devlin, S. M.; van den Brink, M. R. M.; Jenq, R. R.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Addition of tocilizumab to cyclosporine/ MMF for acute graft-vs-host disease (aGVHD) prophylaxis in adult double unit cord blood transplant (dCBT) recipients: Promising preliminary results of a phase II clinical trial
    Meeting Abstract

    Politikos, I.; Maloy, M. A.; Devlin, S. M.; Naputo, K.; Bhatt, V.; Cho, C.; Giralt, S. A.; Gyurkocza, B.; Hanash, A. M.; Papadopoulos, E. B.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save